Journal
BREAST CANCER RESEARCH
Volume 22, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13058-020-01296-5
Keywords
Triple-negative breast cancer; Molecular subtype; Therapeutic target; Therapeutic regimen
Categories
Funding
- National Key Research and Development Program of China [2016YFA0202104]
- National Natural Science Foundation of China [81602730]
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available